Congress ticker disclosure profile

As of July 18 at 5:02 AM EDT

Public STOCK Act rows mentioning

PRAA

A factual page for public Congressional disclosures that reference PRAA. Veridion shows filed rows, disclosed amount ranges, dates, and source links. It does not imply motive or wrongdoing.

90d rows

0

Feed lifetime

15

Member filers

4

Disclosed ranges

$557K

Latest source-stamped receipts

Latest trade Oct 19, 2020

DateMemberActionAmountFiledReceipt
Oct 19, 2020Gilbert CisnerosSell$1,001 to $15,000Nov 5, 2020Open card
May 15, 2020Gilbert CisnerosSell$1,001 to $15,000Jun 16, 2020Open card
Jan 11, 2019Josh GottheimerBuyReceipt pending ingestionJan 31, 2019Receipt pending ingestion
Dec 24, 2018Greg GianforteBuyReceipt pending ingestionDate not disclosedReceipt pending ingestion
Dec 24, 2018Greg GianforteBuy$50,001 to $100,000Date not disclosedOpen card
Dec 12, 2018Josh GottheimerSellReceipt pending ingestionJan 4, 2019Receipt pending ingestion
Nov 21, 2018Greg GianforteSell$50,001 to $100,000Date not disclosedOpen card
Nov 1, 2018Greg GianforteSell$15,001 to $50,000Date not disclosedOpen card
Jan 29, 2018Greg GianforteBuyReceipt pending ingestionDate not disclosedReceipt pending ingestion
Jan 29, 2018Greg GianforteBuy$100,001 to $250,000Date not disclosedOpen card
Dec 29, 2017Greg GianforteSellReceipt pending ingestionDate not disclosedReceipt pending ingestion
Dec 29, 2017Greg GianforteSell$100,001 to $250,000Date not disclosedOpen card
Jul 10, 2017Greg GianforteSellReceipt pending ingestionDate not disclosedReceipt pending ingestion
Jul 10, 2017Greg GianforteSell$1,001 to $15,000Date not disclosedOpen card
Feb 13, 2015Thom TillisSellReceipt pending ingestionFeb 26, 2015Receipt pending ingestion

Source creed

This page is assembled from public STOCK Act disclosure records in the Veridion warehouse. 8 of 15 filed rows include disclosed amount ranges (53%). Rows without ranges stay labeled. Identification only; it does not imply motive or wrongdoing.

Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.